Rocuronium 1.2 — Competitive Intelligence Brief

Rocuronium 1.2 (Rocuronium 1.2) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-depolarizing neuromuscular blocking agent. Area: Anesthesiology.

phase 3 Non-depolarizing neuromuscular blocking agent Nicotinic acetylcholine receptor Anesthesiology Small molecule

Target snapshot

Rocuronium 1.2 (Rocuronium 1.2) — Ain Shams University. Rocuronium is a non-depolarizing neuromuscular blocking agent that competitively antagonizes acetylcholine at the nicotinic acetylcholine receptor on the motor endplate.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rocuronium 1.2 TARGET	Rocuronium 1.2	Ain Shams University	phase 3	Non-depolarizing neuromuscular blocking agent	Nicotinic acetylcholine receptor
Succinylcholine Chloride	SUXAMETHONIUM	Novartis	marketed	Depolarizing Neuromuscular Blocker	Muscle-type nicotinic acetylcholine receptor	1952-01-01
Anesthesia induction,propofol, remifentanil ,cisatracurium	Anesthesia induction,propofol, remifentanil ,cisatracurium	Second Affiliated Hospital of Xi'an Jiaotong University	marketed	Anesthetic combination (GABA-A agonist, opioid, neuromuscular blocker)	GABA-A receptor (propofol), mu opioid receptor (remifentanil), nicotinic acetylcholine receptor at neuromuscular junction (cisatracurium)
Atracurium, TBW	Atracurium, TBW	St. Antonius Hospital	marketed	Non-depolarizing neuromuscular blocking agent	Nicotinic acetylcholine receptor
Patch, Nicotine	Patch, Nicotine	Assistance Publique - Hôpitaux de Paris	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
Spinosad Topical	Spinosad Topical	Cipher Pharmaceuticals Inc.	marketed	Natural insecticide	Nicotinic acetylcholine receptors; GABA-gated chloride channels
bupropion + lozenge	bupropion + lozenge	University of Wisconsin, Madison	marketed	Antidepressant + nicotine replacement therapy	Norepinephrine transporter, dopamine transporter; nicotinic acetylcholine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-depolarizing neuromuscular blocking agent class)

1. University Hospital, Antwerp · 3 drugs in this class
2. Ain Shams University · 2 drugs in this class
3. Merck Sharp & Dohme LLC · 2 drugs in this class
4. Diskapi Yildirim Beyazit Education and Research Hospital · 1 drug in this class
5. Federal University of São Paulo · 1 drug in this class
6. Korea University Guro Hospital · 1 drug in this class
7. Assistance Publique Hopitaux De Marseille · 1 drug in this class
8. Ostfold Hospital Trust · 1 drug in this class
9. St. Antonius Hospital · 1 drug in this class
10. CHU de Reims · 1 drug in this class